Hsu Christine D, Yu Xiaoying, Guo Fangjian, Adekanmbi Victor, Kuo Yong-Fang, Westra Jordan, Berenson Abbey B
Center for Interdisciplinary Research in Women's Health, School of Medicine, University of Texas Medical Branch at Galveston, Galveston, Texas.
Department of Obstetrics and Gynecology, University of Texas Medical Branch at Galveston, Galveston, Texas.
Cancer Epidemiol Biomarkers Prev. 2024 Dec 2;33(12):1678-1682. doi: 10.1158/1055-9965.EPI-24-0225.
Kidney transplant recipients (KTR) have elevated risks of cervical precancers and cancers and guidelines recommend more frequent cervical cancer screening exams. However, little is known about current trends in cervical cancer screening in this unique population. We described patterns in the uptake of cervical cancer screening exams among female KTRs and identified factors associated with screening utilization.
This retrospective cohort study included female KTRs between 20 and 65 years old, with Texas Medicare fee-for-service coverage, who received a transplant between January 1, 2001, and December 31, 2017. We determined the cumulative incidence of receiving cervical cancer screening post-transplant using ICD-9, ICD-10, and CPT codes and assessed factors associated with screening utilization, using the Fine and Gray model to account for competing events. Subdistribution hazard models were used to assess factors associated with screening uptake.
Among 2,653 KTRs meeting the inclusion and exclusion criteria, the 1-, 2-, and 3-year cumulative incidences of initiating a cervical cancer screening exam post-transplant were 31.7% [95% confidence interval (CI), 30.0%-33.6%], 48.0% (95% CI, 46.2%-49.9%), and 58.5% (95% CI, 56.7%-60.3%), respectively. KTRs who were 55 to 64 years old (vs. <45 years old) and those with a higher Charlson Comorbidity Score post-transplant were less likely to receive cervical cancer screening post-transplant.
Cervical cancer screening uptake is low in the years immediately following a kidney transplant.
Our findings highlight a need for interventions to improve cervical cancer screening utilization among kidney transplant recipients. See related In the Spotlight, p. 1554.
肾移植受者(KTR)患宫颈癌前病变和癌症的风险升高,指南建议更频繁地进行宫颈癌筛查。然而,对于这一特殊人群目前的宫颈癌筛查趋势知之甚少。我们描述了女性KTR接受宫颈癌筛查的模式,并确定了与筛查利用相关的因素。
这项回顾性队列研究纳入了20至65岁、有德州医疗保险按服务收费覆盖、在2001年1月1日至2017年12月31日期间接受移植的女性KTR。我们使用ICD - 9、ICD - 10和CPT编码确定移植后接受宫颈癌筛查的累积发病率,并使用Fine和Gray模型评估与筛查利用相关的因素,以考虑竞争事件。使用亚分布风险模型评估与筛查接受相关的因素。
在符合纳入和排除标准的2653名KTR中,移植后开始进行宫颈癌筛查的1年、2年和3年累积发病率分别为31.7% [95%置信区间(CI),30.0% - 33.6%]、48.0%(95% CI,46.2% - 49.9%)和58.5%(95% CI,56.7% - 60.3%)。55至64岁(与<45岁相比)的KTR以及移植后Charlson合并症评分较高的KTR移植后接受宫颈癌筛查的可能性较小。
肾移植后的头几年宫颈癌筛查接受率较低。
我们的研究结果凸显了采取干预措施以提高肾移植受者宫颈癌筛查利用率的必要性。见相关的“聚焦”,第1554页。